目的 了解滁州市艾滋病抗病毒治疗现状,探析艾滋病抗病毒治疗效果改进措施。方法 选取滁州市2018年在治的HIV感染者和艾滋病病人(HIV/AIDS)362例,对其进行CD4+T淋巴细胞计数、HIV病毒载量检测和基因型耐药检测,分析HIV/AIDS免疫学和病毒学指标变化情况,评估抗病毒治疗效果。结果 359例HIV/AIDS接受了HIV病毒载量检测,333例病毒载量小于1 000 cps/ml,病毒抑制率92.7%。362例HIV/AIDS病例治疗后和治疗前CD4+T淋巴计数差异有统计学意义(Z=-11.759,P<0.001);治疗后不同病毒载量组的CD4+T淋巴细胞计数差异有统计学意义(F=18.453,P<0.001),其中<50 cps/ml组与50~1 000 cps/ml组CD4+T淋巴细胞计数明显大于基线值(Z=-11.441,P<0.001;Z=-3.65,P<0.001)。26例HIV/AIDS病例病毒载量>1 000 cp/ml,8例耐药,耐药率为2.2%(8/359)。结论 HIV/AIDS病例抗病毒治疗,有助于改善患者细胞免疫水平。
Abstract
Objective To understand the current situation of AIDS antiviral therapy in Chuzhou City,and to explore measures to improve the effect of AIDS antiviral therapy. Methods A total of 362 patients with HIV/AIDS in Chuzhou City in 2018 were selected.CD4+T lymphocyte count,HIV viral load and genotypic drug resistance were detected.The changes of immunological and virological indexes of HIV/AIDS were analyzed to evaluate the effect of antiviral therapy. Results A total of 359 cases of HIV/AIDS received HIV viral load test,333 cases of viral load less than 1 000 cps/ml,the virus inhibition rate was 92.7%.In 362 cases,there was significant difference in CD4+T lymphocyte count of HIV / AIDS after treatment and before treatment (Z=-11.759,P< 0.001).After treatment,the CD4+T lymphocyte count of different viral load groups was significantly different (F=18.453,P<0.001),and the CD4+T lymphocyte count of viral load <50cps/ml group and 50-1 000 cps/ml group were significantly higher than baseline value (Z=-11.441,P<0.001;Z=-3.65,P<0.001).A total of 26 cases of HIV/AIDS viral load>1 000 cps/ml,8 cases had drug resistance,and the drug resistance rate was 2.2% (8/359). Conclusion Antiviral therapy for HIV / AIDS cases is helpful to improve the cellular immune level of patients.
关键词
HIV/AIDS /
抗病毒治疗 /
病毒载量
Key words
HIV/AIDS /
Antiviral therapy /
Viral load
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Maldarelli F.The role of HIV integration in viral persistence: no more whistling past the proviral graveyard[J].J Clin Invest,2016,126:438-447.
[2] 刘燕芬,黄绍标.广西桂南地区男男性行为人群HIV/AIDS 病人抗病毒治疗效果分析[J].内科,2016,11(3):389-391.
[3] Phillips AN,Pradier C,Lazzain A,et al.Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral experienced patients[J].AIDS,2001,15: 2385-2395.
[4] 中国疾病预防控制中心性病艾滋病预防控制中心.《国家免费艾滋病抗病毒药物治疗手册(第4版)》[M].2016年.
[5] 姚能,何广立,张驰宇.HIV-1病毒载量测定技术的新进展[J].中华检验医学杂志,2011,34(5):472-475.
[6] 中国疾病预防控制中心.《全国艾滋病检测技术规范(2020年修订版)》[M].2020年,3月.
[7] Shen YL,Su B,Wu JJ,et al.The prevalence of transmitted HIV drug resistance among MSM in Anhui province,China.AIDS Res Ther.2014,11(1):19.
[8] 缪礼锋,沈月兰,苏斌,等安徽省485例抗病毒治疗失败艾滋病患者耐药基因型分析[J],中国卫生检验杂志,2019,29(19):2339-2346.
[9] 胡敏,朱碧帆,陆一涵,等.CD4+T淋巴细胞计数检测与HIV病毒载量检测在评价ART效果中的经济性比较及其影响因素[J].中国艾滋病性病,2016,22(4): 232-236.
[10] 张佳峰,郭志宏,黄晶晶,等.NucliSens EasyQ方法在HIV-1病毒载量检测中的应用及质量控制[J].中国卫生检验杂志,2012,29(11):2682-2684.
[11] 邹潇白,贺健梅,张国强,等.湖南省衡阳市2004-2009年艾滋病抗病毒治疗情况分析[J].中国病毒病杂志,2011,1(5):363-366.